GoodRx (NASDAQ:GDRX) Trading 2.1% Higher

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) traded up 2.1% on Wednesday . The company traded as high as $7.05 and last traded at $6.88. 571,937 shares changed hands during mid-day trading, a decline of 64% from the average session volume of 1,603,740 shares. The stock had previously closed at $6.74.

Analyst Upgrades and Downgrades

GDRX has been the topic of several recent analyst reports. TD Cowen boosted their price target on GoodRx from $12.00 to $14.00 and gave the stock an "outperform" rating in a research report on Friday, March 1st. Wells Fargo & Company raised shares of GoodRx from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $7.50 to $10.00 in a research report on Monday, March 25th. UBS Group lifted their price objective on shares of GoodRx from $5.00 to $8.00 and gave the company a "neutral" rating in a research report on Friday, March 1st. Truist Financial upped their target price on shares of GoodRx from $7.50 to $8.00 and gave the company a "hold" rating in a report on Friday, March 1st. Finally, JPMorgan Chase & Co. raised GoodRx from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $7.00 to $10.00 in a report on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $8.78.

GoodRx Stock Performance

The company has a debt-to-equity ratio of 0.85, a current ratio of 7.12 and a quick ratio of 7.12. The stock's 50-day moving average price is $6.81 and its 200-day moving average price is $6.15. The company has a market cap of $2.77 billion, a P/E ratio of -336.83, a PEG ratio of 3.75 and a beta of 1.42.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings data on Thursday, February 29th. The company reported $0.02 earnings per share for the quarter, hitting the consensus estimate of $0.02. GoodRx had a negative net margin of 1.18% and a positive return on equity of 2.45%. The business had revenue of $196.64 million during the quarter, compared to analysts' expectations of $195.59 million. Equities analysts anticipate that GoodRx Holdings, Inc. will post 0.23 EPS for the current year.

Institutional Investors Weigh In On GoodRx

Large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC raised its holdings in GoodRx by 2,602.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 6,919 shares of the company's stock valued at $39,000 after acquiring an additional 6,663 shares in the last quarter. Ensign Peak Advisors Inc acquired a new position in GoodRx in the third quarter valued at about $42,000. Citigroup Inc. lifted its position in GoodRx by 301.7% during the third quarter. Citigroup Inc. now owns 7,997 shares of the company's stock worth $45,000 after purchasing an additional 6,006 shares during the period. Creative Planning acquired a new stake in GoodRx during the fourth quarter worth about $50,000. Finally, Quadrature Capital Ltd acquired a new stake in GoodRx during the third quarter worth about $58,000. Institutional investors and hedge funds own 63.77% of the company's stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.